From the Italian Antiretroviral Resistance Cohort Analysis database, 1104 patients starting ritonavir-boosted darunavir-containing regimen were included as follows: 118 subsequently failed treatment at a median of 11 months (interquartile range: 5-20); 3 years failure proportion: 24.6%. HIV Drug Resistance Database and ANRS interpretation algorithms were associated with a progressive risk prediction of virological failure at adjusted Cox. In contrast, Rega algorithm allows to identify a higher number of patients at risk of failure, without losing statistical significance. Four mutations (V32I, I50V, L76V, I84V) were predictive of failure, the hazard ratio progressively increased by detecting 1 (hazard ratio: 2.0, 95% confidence interval: 1.3 to 3.0), 2 (3.6, 2.0 to 6.6), or 3 of them (9.7, 2.8 to 33.5).

Sterrantino, G., Zaccarelli, M., Trotta, M., DE LUCA, A., Borghi, V., Meraviglia, P., et al. (2012). Interpretation of genotypic resistance to predict darunavir/ritonavir failure in antiretroviral experienced patients. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 59(2), 170-172 [10.1097/QAI.0b013e31823e6518].

Interpretation of genotypic resistance to predict darunavir/ritonavir failure in antiretroviral experienced patients.

DE LUCA A;ZAZZI, MAURIZIO
2012-01-01

Abstract

From the Italian Antiretroviral Resistance Cohort Analysis database, 1104 patients starting ritonavir-boosted darunavir-containing regimen were included as follows: 118 subsequently failed treatment at a median of 11 months (interquartile range: 5-20); 3 years failure proportion: 24.6%. HIV Drug Resistance Database and ANRS interpretation algorithms were associated with a progressive risk prediction of virological failure at adjusted Cox. In contrast, Rega algorithm allows to identify a higher number of patients at risk of failure, without losing statistical significance. Four mutations (V32I, I50V, L76V, I84V) were predictive of failure, the hazard ratio progressively increased by detecting 1 (hazard ratio: 2.0, 95% confidence interval: 1.3 to 3.0), 2 (3.6, 2.0 to 6.6), or 3 of them (9.7, 2.8 to 33.5).
2012
Sterrantino, G., Zaccarelli, M., Trotta, M., DE LUCA, A., Borghi, V., Meraviglia, P., et al. (2012). Interpretation of genotypic resistance to predict darunavir/ritonavir failure in antiretroviral experienced patients. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 59(2), 170-172 [10.1097/QAI.0b013e31823e6518].
File in questo prodotto:
File Dimensione Formato  
Interpretation of genotypic resistance to predict darunavir-ritonavir failure in antiretroviral experienced patients..pdf

non disponibili

Tipologia: PDF editoriale
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 121.52 kB
Formato Adobe PDF
121.52 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11365/11304
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo